CytRx Corporation Share Price Nasdaq
Equities
US2328283013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
06-04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
05-15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 644K 50.57M |
---|---|---|---|---|---|
Net income 2022 | -4M -314M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 1.15M 90M | Net cash position 2023 | 2.04M 160M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.44% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 09/01/22 |
John Caloz
DFI | Director of Finance/CFO | 72 | 30/09/07 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 28/07/21 |
Cary Claiborne
BRD | Director/Board Member | 64 | 26/07/22 |
Joel Caldwell
BRD | Director/Board Member | 69 | 11/07/17 |
1st Jan change | Capi. | |
---|---|---|
+48.75% | 56.95B | |
+39.98% | 40.26B | |
-7.07% | 39.32B | |
-4.42% | 28.37B | |
+12.35% | 26.45B | |
-17.98% | 19.41B | |
+29.22% | 12.54B | |
+26.02% | 12.21B | |
-0.18% | 12.15B |